We are live on ! Find out more
AVAI

Atlas Venture Associates IX Portfolio holdings

AUM $11.8M
1-Year Est. Return 58.35%
This Fund
S&P 500
This Quarter Est. Return
-4.01%
1 Year Est. Return
-58.35%
3 Year Est. Return
-89.8%
5 Year Est. Return
-87.69%
10 Year Est. Return
–
AUM
$33.7M
AUM Growth
-$10.3M
Cap. Flow
-$4.21M
Cap. Flow %
-12.48%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
–
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
COGT icon
Cogent Biosciences
COGT
+$4.21M

Sector Composition

Rank Sector Weight
1 Communication Services 73.63%
2 Healthcare 26.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FIRY
1
Firy Inc
FIRY
$162M
$23.4M 69.26%
1,145,493
– –
SURF
2
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$3.06M 9.08%
2,945,453
– –
SPRO icon
3
Spero Therapeutics
SPRO
$72.4M
$2.75M 8.16%
1,376,968
– –
SYBX
4
DELISTED
Synlogic
SYBX
$2.52M 7.47%
176,798
– –
SNAP icon
5
Snap
SNAP
$8.91B
$1.48M 4.37%
150,160
– –
NTLA icon
6
Intellia Therapeutics
NTLA
$1.64B
$560K 1.66%
10,000
– –
COGT icon
7
Cogent Biosciences
COGT
$7.19B
– –
-466,832
Closed -$4.21M

Similar funds

EEPIS
Evolution Equity Partners II SARL Luxembourg $11.8M AUM 63.6% 1-Year Est. Return
LM
Lockheed Martin Bethesda, Maryland $12.1M AUM 46.13% 1-Year Est. Return
HMP9
Highland Management Partners 9 Cambridge, Massachusetts $12.6M AUM 85.13% 1-Year Est. Return
TCSAM
Tyrus Capital S.A.M. Monaco $10.5M AUM 4.88% 1-Year Est. Return
AEM
ACON Equity Management Washington, District of Columbia $13.8M AUM 62.17% 1-Year Est. Return
PT
Palantir Technologies Denver, Colorado $9.72M AUM 6.46% 1-Year Est. Return
AR
Acacia Research New York $14.1M AUM 50.98% 1-Year Est. Return
MM
Malka Meyer $8.77M AUM 64.77% 1-Year Est. Return

Atlas Venture Associates IX's Q3 2022 Portfolio in Review

As of Q3 2022, Atlas Venture Associates IX held 7 positions worth $33.7M, down 23% from $44M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Atlas Venture Associates IX withdrew a net $4.21M in Q3 2022, closing 1 position. Its most notable exit was Cogent Biosciences, an estimated $4.21M position sold in full.

By sector, the portfolio is most concentrated in Communication Services at 74% of assets, up from 69% a quarter earlier, followed by Healthcare.

  • Atlas Venture Associates IX fully exited Cogent Biosciences in Q3 2022, selling an estimated $4.21M.
  • Atlas Venture Associates IX's ten largest holdings make up 100% of its $33.7M portfolio in Q3 2022.
  • Atlas Venture Associates IX opened 0 new positions and closed 1 in Q3 2022.
  • Atlas Venture Associates IX's portfolio value fell 23% quarter-over-quarter to $33.7M.

Based on Atlas Venture Associates IX's 13F filing for Q3 2022, filed 10 Nov 2022.